BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brady M, Rodger A, Asboe D, Cambiano V, Clutterbuck D, Desai M, Field N, Harbottle J, Jamal Z, McCormack S, Palfreeman A, Portman M, Quinn K, Tenant-Flowers M, Wilkins E, Young I. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. HIV Med 2019;20 Suppl 2:s2-s80. [PMID: 30869189 DOI: 10.1111/hiv.12718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Rutstein SE, Smith DK, Dalal S, Baggaley RC, Cohen MS. Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. Lancet HIV 2020;7:e721-30. [PMID: 32861269 DOI: 10.1016/S2352-3018(20)30203-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Garcia Iglesias J. From training wheels to chemical condoms: Exploring narratives of PrEP discontinuation. Health (London) 2021;:13634593211005177. [PMID: 33757365 DOI: 10.1177/13634593211005177] [Reference Citation Analysis]
3 Saunders J, Gill ON, Delpech V, Estcourt C; Five Nations (England, Scotland, Wales, Northern Ireland, Republic of Ireland) PrEP Minimum Dataset Working Group. Minimum dataset for monitoring national human immunodeficiency virus pre-exposure prophylaxis (HIV PrEP) programmes: a five-nation consensus, 2019. Euro Surveill 2021;26. [PMID: 34114539 DOI: 10.2807/1560-7917.ES.2021.26.23.2001595] [Reference Citation Analysis]
4 Chilaka VN, Konje JC. HIV in pregnancy - An update. Eur J Obstet Gynecol Reprod Biol 2021;256:484-91. [PMID: 33246666 DOI: 10.1016/j.ejogrb.2020.11.034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Cornelisse VJ, Lal L, Price B, Ryan KE, Bell C, Owen L, Wright EJ. Interest in Switching to On-Demand HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Users of Daily PrEP: An Online Survey. Open Forum Infect Dis 2019;6:ofz287. [PMID: 31304192 DOI: 10.1093/ofid/ofz287] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
6 Hibbert MP, Wolton A, Weeks H, Ross M, Brett CE, Porcellato LA, Hope VD. Psychosocial and sexual factors associated with recent sexual health clinic attendance and HIV testing among trans people in the UK. BMJ Sex Reprod Health 2020;46:116-25. [PMID: 31666303 DOI: 10.1136/bmjsrh-2019-200375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Cresswell F, Asanati K, Bhagani S, Boffito M, Delpech V, Ellis J, Fox J, Furness L, Kingston M, Mansouri M, Samarawickrama A, Smithson K, Sparrowhawk A, Rafferty P, Roper T, Waters L, Rodger A, Gupta N. UK guideline for the use of HIV post-exposure prophylaxis 2021. HIV Med 2022. [PMID: 35166004 DOI: 10.1111/hiv.13208] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 O'Halloran C, Owen G, Croxford S, Sims LB, Gill ON, Nutland W, Delpech V. Current experiences of accessing and using HIV pre-exposure prophylaxis (PrEP) in the United Kingdom: a cross-sectional online survey, May to July 2019. Euro Surveill 2019;24. [PMID: 31796157 DOI: 10.2807/1560-7917.ES.2019.24.48.1900693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Estcourt C, Yeung A, Nandwani R, Goldberg D, Cullen B, Steedman N, Wallace L, Hutchinson S. Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. AIDS 2021;35:665-73. [PMID: 33290298 DOI: 10.1097/QAD.0000000000002790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
10 Bradshaw D, Taylor GP. HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review. Front Med 2022;9:881547. [DOI: 10.3389/fmed.2022.881547] [Reference Citation Analysis]
11 Smith M, Elliott L, Hutchinson SJ, Metcalfe R, Flowers P, McAuley A. Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study. Int J Drug Policy 2021;88:103033. [PMID: 33249313 DOI: 10.1016/j.drugpo.2020.103033] [Reference Citation Analysis]
12 Reis RK, Sousa LRM, Melo ES, Fernandes NM, Sorensen W, Gir E. Predictors of HIV Status Disclosure to Sexual Partners Among People Living with HIV in Brazil. AIDS Behav 2021;25:3538-46. [PMID: 34173896 DOI: 10.1007/s10461-021-03362-1] [Reference Citation Analysis]
13 Hall EW, Wang L, Huang X, Sullivan PS, Siegler AJ. Assessing the performance of international pre-exposure prophylaxis (PrEP) eligibility guidelines in a cohort of Chinese MSM, Beijing, China 2009 to 2016. J Int AIDS Soc 2020;23:e25653. [PMID: 33345453 DOI: 10.1002/jia2.25653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 White E, Dunn DT, Desai M, Gafos M, Kirwan P, Sullivan AK, Clarke A, McCormack S; PROUD study group. Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial. Sex Transm Infect 2019;95:449-54. [PMID: 30918121 DOI: 10.1136/sextrans-2018-053808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
15 Hanum N, Cambiano V, Sewell J, Phillips AN, Rodger AJ, Speakman A, Nwokolo N, Asboe D, Gilson R, Clarke A, Miltz AR, Collins S, Lampe FC; AURAH2 Study Group. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health 2020;5:e501-11. [PMID: 32888443 DOI: 10.1016/S2468-2667(20)30186-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]